Dogwood Therapeutics DWTX Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's accrued expenses and other liabilities?
- Dogwood Therapeutics (DWTX) reported accrued expenses and other liabilities of $187.83K in Q1 2026.
- How has Dogwood Therapeutics's accrued expenses and other liabilities changed year-over-year?
- Dogwood Therapeutics's accrued expenses and other liabilities increased by 202.4% year-over-year, from -$183.35K to $187.83K.
- What is the long-term trend for Dogwood Therapeutics's accrued expenses and other liabilities?
- Over 2 years (2023 to 2025), Dogwood Therapeutics's accrued expenses and other liabilities has grown at a 65.0% compound annual growth rate (CAGR), from -$223.46K to $608.29K.